THE NHS must “get with the times” and speed up its roll-out of weight-loss jabs, says Health Secretary Wes Streeting. He ...

Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

As weight loss medications like Ozempic continue to gain popular, experts and patients are noticing varying effects of the drugs for people with eating disorders.

Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. | Under a mutual agreement with ...

U.S.-listed shares of Novo Nordisk declined in the opening minutes of trading Friday on the surprise news that CEO Lars ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

While those taking semaglutide (Wegovy) and tirzepatide (Mounjaro) lost double the amount of weight compared with people ...

Ohio Attorney General Dave Yost sent letters to 14 medical spas warning them to stop making false or misleading claims about ...